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Background: Central venous access devices in fluoropyrimidine therapy are associated with complications; however, reliable data
are lacking regarding their natural history, associated complications and infusion pump performance in patients with metastatic
colorectal cancer.
Methods: We assessed device placement, use during treatment, associated clinical outcomes and infusion pump perfomance in
the NO16966 trial.
Results: Device replacement was more common with FOLFOX-4 (5-fluorouracil (5-FU)þoxaliplatin) than XELOX (capecitabineþ
oxaliplatin) (14.1% vs 5.1%). Baseline device-associated events and post-baseline removal-/placement-related events occurred
more frequently with FOLFOX-4 than XELOX (11.5% vs 2.4% and 8.5% vs 2.1%). Pump malfunctions, primarily infusion
accelerations in 16% of patients, occurred within 1.6–4.3% of cycles. Fluoropyrimidine-associated grade 3/4 toxicity was increased
in FOLFOX-4-treated patients experiencing a malfunction compared with those who did not (97 out of 155 vs 452 out of 825
patients), predominantly with increased grade 3/4 neutropenia (53.5% vs 39.8%). Febrile neutropenia rates were comparable
between patient cohorts±malfunction. Efficacy outcomes were similar in patient cohorts±malfunction.
Conclusions: Central venous access device removal or replacement was common and more frequent in patients receiving
FOLFOX-4. Pump malfunctions were also common and were associated with increased rates of grade 3/4 haematological adverse
events. Oral fluoropyrimidine-based regimens may be preferable to infusional 5-FU based on these findings.
Fluoropyrimidines form the foundation of the vast majority of
chemotherapy regimens used in the treatment of metastatic
colorectal cancer (mCRC), and they can take the form of
intravenous 5-fluorouracil (5-FU; by continuous or bolus infusion)
or oral formulations (capecitabine). Fluoropyrimidine-based
regimens include XELOX (oral capecitabine plus infusional
oxaliplatin), FOLFOX (infusional leucovorin (LV), 5-FU and
oxaliplatin) and FOLFIRI (infusional LV, 5-FU and irinotecan),
each of which has a well-established role in the management of
patients with mCRC. These regimens are now included in the key
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evidence-based practice guidelines in Europe and the United States
(Van Cutsem et al, 2010; NCCN, 2013).
The preferred 5-FU administration schedule for the FOLFOX or
FOLFIRI regimens is intravenous infusions of either 22 or 46 h
duration. Patients receiving these regimens usually require
placement of a central venous access device (CVAD), as treatment
involves repeated and prolonged infusions. Catheter insertion
requires skilled personnel, and it is usually performed under local
anaesthesia, taking B30–50min, on average, to complete
(Gann and Sardi, 2003; Shen-Gunther et al, 2003). Central venous
access device placements are often associated with complications
such as infections and venous thrombosis, resulting in antibiotic
use, hospitalisation and CVAD replacements (Debourdeau et al,
2009; Beckers et al, 2010). A number of other complications have
been observed, including insertion-related problems (McGee and
Gould, 2003) and catheter sheath formation (Xiang et al, 1998).
Previous studies have reported CVAD-associated complications in
8–15% of patients with CRC (Martoni et al, 2006; Inaba et al, 2007;
Kawamura et al, 2008). In a randomised phase II study of
patients with advanced CRC treated with XELOX or FOLFOX
(utilising protracted infusion of 5-FU and oxaliplatin), venous line
complications occurred in 15% of FOLFOX-treated patients, which
resulted in suspension or cessation of treatment (Martoni et al,
2006). The INT-0153 study compared the clinical efficacy of
continuous infusion 5-FU (CIFU) plus levamisole vs bolus 5-FU/
LV plus levamisole in the adjuvant treatment of patients with stage
III and high-risk stage II colon cancer, and found that nearly twice
as many patients discontinued CIFU/levamisole than those who
discontinued bolus 5-FU/LV/levamisole (106 out of 460 vs 64 out
of 459, respectively), despite significantly higher rates of grade 4
toxicities in the bolus arm (5% vs 39%). The main adverse events
observed were haematological and gastrointestinal in nature. Early
treatment discontinuation in the CIFU arm was more often
associated with non-life-threatening adverse events, such as hand–
foot syndrome, or events associated with the delivery and
administration of CIFU, such as pump therapy logistics, pump
malfunctions, CVAD-associated thrombosis and catheter-related
neck pain (Poplin et al, 2005).
There is, presently, a paucity of data on the natural history of
CVADs and CVAD-associated complications from large studies of
patients with mCRC. Moreover, data regarding the performance
and reliability of infusional pumps have not been prospectively
reported in the scientific literature. Herein, we report the largest
prospective evaluation of CVAD placement and use during
treatment, and of CVAD-associated clinical outcomes. Data were
obtained from the NO16966 trial, which was a phase III,
randomised investigation into the comparative efficacy of XELOX
and FOLFOX-4 in the front-line treatment of patients with mCRC.
When used, CVADs were placed in patients receiving XELOX as a
result of the oxaliplatin component of the regimen.
PATIENTS AND METHODS
Study design. The design of the NO16966 study and the patient
population have been described previously (Cassidy et al, 2008).
Based on the results of the pivotal trial evaluating bevacizumab in
mCRC, the trial design was amended after patient accrual had
begun (Saltz et al, 2007). The amended trial used a 2 2 factorial
design and randomised patients to either FOLFOX-4 or XELOX in
combination with bevacizumab or placebo (Cassidy et al, 2008).
The primary endpoint was progression-free survival. During the
study, data were prospectively collected regarding CVAD place-
ments (but not the specific type of CVAD) or CVAD removals
and/or replacements, and adverse events associated with CVAD
insertion, removal and replacement (graded according to the
National Cancer Institute Common Terminology Criteria, version
3.0 (National Cancer Institute, 2006); available for initial place-
ments only). Central venous access device placement was at the
discretion of the investigator. Data were prospectively collected on
the presence of an infusion pump malfunction during a treatment
cycle, as well as start and stop times associated with individual
infusions of 5-FU. Adherence to oral capecitabine was assessed by
pill counts at the time of patient clinic visits.
NO16966 was performed in accordance with the Declaration of
Helsinki and Good Clinical Practice Guidelines. Written informed
consent was obtained from all patients participating in the study.
Approval of the protocol was obtained from an independent ethics
committee or the institutional review board of each site.
Patients. The entire NO16966 trial population, including patients
treated with bevacizumab or placebo, was used for this evaluation.
The safety population includes all randomised patients who
received at least one dose of any component of the study regimens.
Patients were recruited between July 2003 and February 2005.
Statistical analyses. Analyses were derived from the safety
population and included patients with available CVAD data.
Patients were grouped into cohorts consisting of the total safety
population or subsets, dependent on the specific analyses
performed: time to first CVAD placement (in patients with a first
placement after treatment start); time from first placement to
first replacement (in patients with a first removal); and time from
first placement to second replacement (in patients with a second
removal).
Incidence rates for each cohort were compared between the
XELOX and FOLFOX-4 regimens using the Pearson’s w2-test.
Median times to each endpoint (±s.e.) were estimated using the
Kaplan–Meier method, and the distributions were compared using
the log-rank test. As the patient cohorts selected could have been
subsets of the total safety population, results of statistical tests
are provided for descriptive purposes only.
Central venous access device-associated complications and
adverse events, along with incidence rates, were summarised in
terms of those reported after CVAD placement on the baseline case
report form (CRF), and those reported during treatment after
CVAD removal/replacement on a treatment cycle-specific CRF.
Progression-free survival and overall survival among patients
treated with FOLFOX-4 who experienced a pump malfunction
during treatment were compared with those who did not using the
Kaplan–Meier method. The total number of patients experiencing
X1 grade 3/4 adverse events of relevance to fluoropyrimidine
therapy were pooled and compared using the w2-test. Only the
highest grade reported per adverse event and patient was included
for statistical analyses. Pump malfunction data were recorded for
5-FU infusions only, and therefore relate only to patients treated
with FOLFOX-4.
Multivariate logistic regression analyses explored the potential
independent association between study treatment (FOLFOX-4 vs
XELOX) and the risk of CVAD-related adverse events post-
implantation/insertion and with respect to the FOLFOX-4 patients
alone, the association of pump malfunctions and risk of grade
3/4 adverse events of special interest for fluoropyrimidines/
neutropenia.
Cox proportional hazard regression models were performed for
progression-free survival and overall survival, and logistic regres-
sion analyses were performed for overall response rate.
The additional covariates used in the multivariate logistic and
the Cox regression analyses included age (o65 vs X65 years),
gender, baseline ECOG performance status (0 vs 1/2), number
of metastatic sites at baseline (o2 vs X2 organs) and infusion
duration (o22 vs X22 h). The hypothesis testing of all covariates
was two-sided at a¼ 0.025.
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RESULTS
Patient characteristics. The patient baseline demographics for the
NO16966 trial has been described previously (Cassidy et al, 2008).
Patient demographics and disease characteristics of the cohorts
used to analyse CVAD-related complications and pump malfunc-
tions were generally comparable both to the overall population
of the study and to each other (Supplementary Tables 1 and 2).
The disposition of patients and availability of the derived data
regarding CVAD placement are outlined in Figure 1.
CVAD placement. Initial CVAD placement data were available
for 1341 out of 1998 patients (67%, Table 1). Central venous access
devices were placed in 1194 patients (60%) on/before the treatment
start date, with 147 (7%) having a CVAD placed after treatment
start.
While CVADs were placed on/before the treatment start date in
797 patients receiving FOLFOX-4 and 397 patients receiving
XELOX, placements were performed after treatment start in 91 and
56 patients receiving FOLFOX-4 and XELOX, respectively.
For patients with a first CVAD placement after treatment start,
the time to first CVAD placement was shorter in patients
receiving FOLFOX-4 compared with those receiving XELOX. The
median time to first placement was 13.0 days after treatment start
(95% confidence interval (CI): 10–15 days) for patients treated
with FOLFOX-4, and 81.0 days after treatment start (95% CI:
60–109 days) for patients treated with XELOX (log-rank test
Po0.0001; Figure 2 and Supplementary Table 3).
CVAD removal/replacement. A higher proportion of patients
treated with FOLFOX-4 required a CVAD replacement after
removal of their first CVAD than those treated with XELOX
(125 out of 888 (14.1%) vs 23 out of 453 (5.1%) patients,
respectively). Kaplan–Meier survival analyses estimated the
median times to replacement to be similar in the analytic cohorts
(Figure 3 and Supplementary Table 3). A similar result was
observed for the subpopulation of patients with a first replacement
1998 Patients treated
(FOLFOX-4: 990 patients,
XELOX: 1008 patients)
1341 Patients
with first placement
(FOLFOX-4: 888 patients,
XELOX: 453 patients)
657 Patients without
first placement information
(FOLFOX-4: 102 patients,
XELOX: 555 patients)
185 Patients with first
removal on/after date
of first placement
(FOLFOX-4: 156 patients,
XELOX: 29 patients)
1194 Patients with first
placement at BL
(FOLFOX-4: 797 patients,
XELOX: 397 patients)
147 Patients with first
placement post-BL
(FOLFOX-4: 91 patients,
XELOX: 56 patients)
26 Patients with first
removal on/after date
of first placement
(FOLFOX-4: 15 patients,
XELOX: 11 patients)
1 FOLFOX-4 patient with
first removal information
only and 1 FOLFOX-4
patient with removal before
‘first placement’
13 Patients with first
replacement on/after date
of first removal
(FOLFOX-4: 7 patients,
XELOX: 6 patients)
3 Patients with second
removal on/after date
of first replacement
(FOLFOX-4: 3 patients,
XELOX: 0 patients)
1 Patient with second
replacement on/after date
of second removal
(FOLFOX-4: 1 patient,
XELOX: 0 patients)
135 Patients with first
replacement on/after date
of first removal
(FOLFOX-4: 118 patients,
XELOX: 17 patients)
57 Patients with second
removal on/after date
of first replacement
(FOLFOX-4: 53 patients,
XELOX: 4 patients)
36 Patients with second
replacement on/after date
of second removal
(FOLFOX-4: 33 patients,
XELOX: patients)
Figure 1. Distribution of patient data. Abbreviations: BL¼baseline (placement on/before the start of treatment); Post-BL¼post-baseline
(placement after the start of treatment).
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after a first removal treated with chemotherapy alone: no
significant differences were seen regardless of chemotherapy
regimen or use of bevacizumab. Second replacements were
uncommon and occurred mainly in patients treated with
chemotherapy alone (data not shown).
CVAD-associated complications and adverse events. Adverse
events associated with CVAD placement and use were relatively
uncommon, and the majority of events were associated with
placement. More than 80% of patients with CVAD placements had
their first CVAD-related adverse event within 120 days after initial
placement (Figure 4). Central venous access device-associated
adverse events after initial placement occurred in 138 out of 1998
patients with a baseline placement (6.9%). Catheter/insertion site
events were the most frequent events, occuring in 129 out of 1998
patients (6.5%), and were associated with the catheter site in 154
out of 169 (91.1%) of all cases. Common adverse events in this
category included pain, haematoma and haemorrhage. Central
venous access device-associated adverse events occurred more
frequently at baseline placement with FOLFOX-4 compared with
XELOX (11.5% vs 2.4%; Table 2). Adverse events associated with
CVAD removal or replacement were also more frequent in patients
receiving FOLFOX-4 than in those receiving XELOX (8.5% vs
2.1%, respectively; Table 3). The most common adverse events
were equally distributed between CVAD site infections and other
local complications. These events included central line/
site infection, catheter site cellulitis, catheter thrombosis and
catheter-related complications that were not otherwise specified.
The CVAD-associated adverse event rates for FOLFOX-4 or
XELOX plus bevacizumab were similar to those for chemotherapy
alone (data not shown). Multivariate logistic regression analyses
confirmed that treatment was independently associated with the
Table 1. CVAD placement data for patients treated in the NO16966 study (patients in the safety population who had placement data)
FOLFOX-4, n¼888a XELOX, n¼453a
Patients, n (%)
First placement on/before
treatment start,
n¼797
First placement after
treatment start,
n¼91
First placement on/before
treatment start,
n¼397
First placement after
treatment start,
n¼56
First removal on/after date of
first placementb
156 (19.6) 15 (16.5) 29 (7.3) 11 (19.6)
First replacement on/after date
of first removalc
118 (14.8) 7 (7.7) 17 (4.3) 6 (10.7)
Second removal on/after date of
first replacementd
53 (6.6) 3 (3.3) 4 (1.0) 0 (0)
Second replacement on/after
date of second removale
33 (4.1) 1 (1.1) 3 (0.8) 0 (0)
Abbreviations: CVAD¼ central venous access device; FOLFOX-4¼ 5-fluorouracilþoxaliplatin; XELOX¼ capecitabineþoxaliplatin.
aPatients with first placement data.
bRegardless of whether the first placement was on/before or after the treatment start date.
cPatients with a first removal.
dPatients with a first replacement.
ePatients with a second removal.
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Figure 2. Kaplan–Meier curve of time to first CVAD placement among
patients with first CVAD placements after treatment start, treated
with FOLFOX-4±bevacizumab/placebo or XELOX±bevacizumab/
placebo (patients in the safety population who had placement data).
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Figure 3. Kaplan–Meier curve of time from first CVAD placement to
first CVAD replacement among patients with first replacement (after
first removal), treated with FOLFOX-4±bevacizumab/placebo or
XELOX±bevacizumab/placebo (patients in the safety population who
had placement data).
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risk of CVAD-associated complications (odds ratio (OR) 0.23,
97.5% CI: 0.13–0.40, Po0.0001), including general disorders and
administration site conditions, for example, catheter thrombosis,
catheter-related complications, catheter site pain/inflammation/
discharge and pyrexia (OR 0.17, 97.5% CI: 0.07–0.42; Po0.0001).
Pump malfunctions. The study protocol allowed for the use of
disposable, single-use pumps or for reusable, programmable
pumps for the 5-FU infusion according to investigator’s choice
and site preference. The pump type was recorded; however, more
detailed information on the manufacturer or model was not
collected. Disposable and reusable pumps were used equally across
treatment cycles. Pump malfunctions during 5-FU infusion
occurred in 16% of patients treated with FOLFOX-4. The
malfunction rate was consistent across cycles (1.3–4.9%) and over
time (Figure 5). Disposable, single-use pumps malfunctioned more
frequently than reusable, programmable pumps.
Among the group of patients experiencing a pump malfunction,
the most common issue was related to accelerated delivery of 5-FU,
with 61% of patients who experienced a pump malfunction having
an infusion duration of o22 h vs 11% of patients without a pump
malfunction (Table 4). The majority of patients not experiencing a
malfunction (88%) had an infusion duration of 22–24 h, vs 31.8%
in patients experiencing a pump malfunction.
The rates of grade 3/4 adverse events specifically related to
fluoropyrimidine treatment in patients with FOLFOX-4 who
experienced a pump malfunction compared with those who did
not are shown in Table 5. Overall, there was a trend towards
increased adverse events in patients who experienced a malfunc-
tion (97 out of 155 vs 452 out of 825 patients; w2-test; P¼ 0.0729).
The incidence of grade 3/4 neutropenia was significantly higher in
patients experiencing a malfunction (83 out of 155 (53.5%) vs 328
out of 825 (39.8%) patients, respectively; P¼ 0.0009). Data were
Table 2. Adverse events reported after CVAD placement on the baseline
CRF page in 40.1% of patients treated with FOLFOX-4 or XELOX
(patients in the safety population who had placement data)
Adverse event, n (%)
FOLFOX-4,
n¼990
XELOX,
n¼1008
Total patients with X1 adverse events 114 (11.5) 24 (2.4)
General disorders and administration site
conditions
106 (10.7) 23 (2.3)
Catheter site pain 59 (6.0) 14 (1.4)
Catheter site haematoma 34 (3.4) 5 (0.5)
Catheter site haemorrhage 21 (2.1) 2 (0.2)
Catheter site erythema 3 (0.3) 1 (0.1)
Catheter site swelling 2 (0.2) 1 (0.1)
Respiratory, thoracic and mediastinal disorders 5 (0.5) 1 (0.1)
Pneumothorax 2 (0.2) 1 (0.1)
Injury, poisoning and procedural complications 2 (0.2) 0 (0)
Procedural nausea 2 (0.2) 0 (0)
Nervous system disorders 2 (0.2) 0 (0)
Dizziness 2 (0.2) 0 (0)
Abbreviations: CRF¼ case report form; CVAD¼ central venous access device;
FOLFOX-4¼ 5-fluorouracilþoxaliplatin; XELOX¼ capecitabineþoxaliplatin.
Table 3. Adverse events reported after CVAD replacement or removal on
a treatment cycle CRF page in40.1% of patients treated with FOLFOX-4
or XELOX (patients in the safety population who had placement data)
Adverse event, n (%)
FOLFOX-4,
n¼990
XELOX,
n¼1008
Total patients with X1 adverse events 84 (8.5) 21 (2.1)
Infections and infestations 42 (4.2) 8 (0.8)
Central line infection 29 (2.9) 4 (0.4)
Infection 5 (0.5) 0 (0)
Catheter site infection 2 (0.2) 1 (0.1)
Catheter site cellulitis 2 (0.2) 0 (0)
Septic shock 2 (0.2) 0 (0)
General disorders and administration site
conditions
40 (4.0) 7 (0.7)
Catheter thrombosis 17 (1.7) 3 (0.3)
Catheter-related complication 11 (1.1) 3 (0.3)
Pyrexia 5 (0.5) 0 (0)
Catheter site pain 3 (0.3) 0 (0)
Vascular disorders 3 (0.3) 4 (0.4)
Thrombophlebitis 2 (0.2) 0 (0)
Thrombosis 0 (0) 2 (0.2)
Abbreviations: CRF¼ case report form; CVAD¼ central venous access device;
FOLFOX-4¼ 5-fluorouracilþoxaliplatin; XELOX¼ capecitabineþoxaliplatin.
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not, however, available to establish whether the episodes of
neutropenia occured during treatment cycles where there was a
pump malfunction. Rates of neutropenic sepsis were comparable
between the two cohorts as were rates of gastrointestinal side
effects. Multivariate logistic analyses, restricted to FOLFOX-4-
treated patients (as only they were exposed to a pump), showed
that pump malfunction was associated with an increased risk of
grade 3/4 neutropenia (OR 1.57, 97.5% CI: 1.03–2.38; P¼ 0.00165)
and a numerical trend for increased risk of grade 3/4 adverse
events of special interest for fluoropyrimidines such as neutropenia
and gastrointestinal effects (OR 1.25, 97.5% CI: 0.82–1.92;
P¼ 0.2361).
Clinical efficacy outcomes were similar between patients who
experienced a pump malfunction and those who did not; the
objective response rate (56.1% vs 48.1%), progression-free survival
(median 284 days vs 252 days) and overall survival (median 683
days vs 583 days) parameters were comparable between groups.
There was no evidence to suggest a detrimental effect of pump
malfunction on efficacy outcomes, as assessed by multivariate
Cox proportional hazards analyses of progression-free survival
and overall survival, and multivariate logistic regression analyses of
overall response rate.
Capecitabine compliance. Patients treated with oral capecitabine
showed high levels of adherence, as assessed by pill counts
at the end of each treatment cycle. The median adherence ratio
(pills taken vs planned; 1.00 indicated perfect adherence) was 1.00
(perfect adherence) across analytical cohorts: XELOX¼ 1.00 (range
0.70–4.67), XELOX plus placebo¼ 1.00 (0.30–3.00) and XELOX
plus bevacizumab¼ 1.00 (0.71–13.94).
DISCUSSION
The NO16966 trial is the largest patient population from a
randomised phase III clinical study to provide data regarding the
use of CVADs. Based on this study, it is clear that CVAD-
associated complications, the requirement for CVAD replacement
and the occurrence of pump malfunctions during treatment were
common. Of note, patients treated with XELOX±bevacizumab/
placebo required fewer subsequent replacements and experienced
fewer CVAD-associated adverse events than those treated with
FOLFOX-4±bevacizumab/placebo. As such, differences in
CVAD-associated complication rates between patients treated with
FOLFOX-4 plus bevacizumab or XELOX plus bevacizumab
appear to result from the continued repeated use of infusional
5-FU associated with the FOLFOX-4 regimen.
Thrombosis and infections are well-known complications
of CVADs. However, in the NO16966 study, we observed lower
or comparable rates of thrombosis compared with 1–18% in several
other studies involving CVADs (where patients did not receive
prophylaxis against thrombosis) (Verso et al, 2005; Karthaus et al,
2006; Fagnani et al, 2007; Ng et al, 2007; Arau´jo et al, 2008; Surov
et al, 2008; Biffi et al, 2009; Starling et al, 2009; Beckers et al, 2010;
Cavanna et al, 2010; Barbetakis et al, 2011; Kriegel et al, 2011;
Saber et al, 2011). We also observed lower or comparable rates of
infection than the 2.4–58.3% previously reported rates (Karthaus
et al, 2006; Fagnani et al, 2007; Ng et al, 2007; Beckers et al, 2010;
Cavanna et al, 2010; Barbetakis et al, 2011), although even lower
infection rates of 0.4–2.5% have also been reported in some studies
(Arau´jo et al, 2008; Biffi et al, 2009). Consistent with our findings,
adverse events have been reported to occur relatively early
following CVAD placement (Fagnani et al, 2007; Inaba et al,
2007; Ng et al, 2007; Cavanna et al, 2010; Saber et al, 2011).
In the INT-0153 study (Poplin et al, 2005), catheter-related
complications and pump issues (logistics and malfunctions) may
have adversely impacted the delivery of CIFU, and the authors
speculated that this may, in part, explain why CIFU did not
improve clinical outcomes when compared with bolus 5-FU.
Pump malfunctions during FOLFOX-4 treatment were
relatively common in NO16966 and occurred in a relatively
high proportion of patients (16%), with malfunctions reported in
1.3–4.9% of patients across treatment cycles. The majority of
malfunctions were observed for disposable pumps; however,
programmable pump malfunctions constituted B20% of the total
malfunctioning pumps. Shorter infusion times were associated
with malfunctions in approximately two-thirds of infusions.
Fluoropyrimidine-induced cytotoxicity is known to be both
dose- and schedule-dependent (The Meta-Analysis Group In
Cancer, 1998; Lamont and Schilsky, 1999). These pharmacological
properties raised questions regarding the potential association of
altered drug delivery by pump malfunctions and risk for
Table 4. Treatment infusion duration for infusions with and without a
pump malfunction (safety populations for the FOLFOX-4, FOLFOX-4
þplacebo and FOLFOXþbevacizumab groups)
Duration
Malfunction,
n¼559 infusions
No malfunction,
n¼21497 infusions
o12h, n (%) 22 (3.9) 58 (0.3)
12–14 h, n (%) 1 (0.2) 20 (0.1)
14–16 h, n (%) 4 (0.7) 16 (0.1)
16–18 h, n (%) 35 (6.3) 114 (0.5)
18–20 h, n (%) 96 (17.2) 427 (2.0)
20–22 h, n (%) 183 (32.7) 1800 (8.4)
22–24 h, n (%) 178 (31.8) 18851 (87.7)
24–26 h, n (%) 27 (4.8) 148 (0.7)
426 h, n (%) 13 (2.3) 63 (0.3)
Abbreviation: FOLFOX-4¼ 5-fluorouracilþoxaliplatin.
Table 5. Grade 3/4 adverse events specifically related to
fluoropyrimidine treatment across all cycles of patients treated with
FOLFOX-4, based on the presence of a pump malfunction (patients in
the safety population who had placement data)
Adverse events, n (%)
Malfunction,
n¼155
No malfunction,
n¼825
Total patients withX1 adverse eventsa 107 (69.0) 496 (60.1)
Gastrointestinal disordersa 25 (16.1) 157 (19.0)
Diarrhoeab 15 (9.7) 103 (12.5)
Nauseab 7 (4.5) 38 (4.6)
Vomitingb 7 (4.5) 39 (4.7)
Stomatitis (all)b 3 (1.9) 20 (2.4)
Blood and lymphatic system disordersa 91 (58.7) 361 (43.8)
Neutropeniab 83 (53.5) 328 (39.8)
Febrile neutropeniab 12 (7.7) 33 (4.0)
Granulocytopeniab 1 (0.6) 4 (0.5)
Skin and subcutaneous tissue disordersa 2 (1.3) 12 (1.5)
Hand–foot syndromeb 2 (1.3) 12 (1.5)
Infections and infestationsa 0 (0) 6 (0.7)
Neutropenic sepsisb 0 (0) 5 (0.6)
Neutropenic infectionb 0 (0) 1 (0.1)
Abbreviation: FOLFOX-4¼ 5-fluorouracilþoxaliplatin.
aPatients who experienced different adverse events at grade 3 and 4 were counted under
the most severe intensity for each adverse event.
bPatients were counted once under the most severe intensity.
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adverse events as well as efficacy outcomes. Increased rates of grade
3/4 adverse events specifically related to fluoropyrimidines
(predominantly neutropenia) were observed in patients who
experienced a pump malfunction. Nevertheless, clinical efficacy
outcomes appeared to be comparable regardless of malfunction.
The strength of the present analysis comes from the fact that the
NO16966 trial included the largest patient population, to date, that
provided data on the use of CVADs in mCRC. However, one of the
main limitations of this analysis relates to the fact that information
on the specific types of catheters used was not collected.
Presumably, the catheter type/insertion for both regimens was
based on local standards of care, and as a result, the specific type of
catheter may have impacted on the subsequent incidence of
adverse events. However, it should be noted that the overall
incidence and pattern of onset of adverse events were comparable
to those previously reported in the literature. Another potential
limitation of our analysis was that CVAD-associated adverse events
were only reported during the study treatment period. These events
were only recorded during placement and/or removal/replacement
of CVADs using the specific CRF, and events were tracked only
during the study treatment period. All other events were collected
together regardless of whether they were caused by a CVAD,
underlying cancer clinical state, study treatment regimens or other
reasons. The other potential reasons for CVAD-associated adverse
events were tracked using general adverse event CRFs throughout
the study treatment period and for an additional 4 weeks after
discontinuation of study treatment. Of note, the rate of hand–foot
syndrome was similar in both arms.
Treatment with the oral fluoropyrimidine, capecitabine, effec-
tively avoids many of the resource issues associated with CVADs. A
medical resource utilisation companion study to the NO16966 trial
showed that the number of drug administration visits and CVADs
placed was reduced with XELOX vs FOLFOX-4, despite the addition
of intravenous oxaliplatin and bevacizumab (Scheithauer et al,
2007). A separate United States cost minimisation analysis of
NO16966 reported that the total estimated direct costs for XELOX
without bevacizumab were $1300 less than for FOLFOX-4 without
bevacizumab, and $3100 less for XELOX with bevacizumab than
FOLFOX-4 with bevacizumab. The estimated indirect costs for
XELOX were $1500–$1700 less than for FOLFOX (Garrison et al,
2007). Similarly, a cost minimisation analysis of XELOX vs
FOLFOX-6 showed that XELOX is associated with significantly
reduced mean disease management costs compared with FOLFOX-6
(h12918 vs h17226; Po0.001). Patients treated with XELOX also
spend less time at the hospital than patients treated with FOLFOX-6
(Conroy et al, 2010; Perrocheau et al, 2010). A review of 4973
patients in the Thomson Healthcare MarketScan Commercial
Claims and Encounters and Medicare Supplemental and Coordina-
tion of Benefits databases showed that capecitabine-based therapy
was associated with fewer complications than 5-FU-based therapy
(Chu et al, 2009). As a result, the mean predicted monthly cost of
complications associated with 5-FU plus oxaliplatin was higher than
that of those associated with XELOX (difference¼ $1165, 95% CI:
$892–$1595). Notably, no difference in total costs were observed
when drug acquisition, administration and complication costs were
combined (Chu et al, 2009).
In summary, this study provides additional insights regarding
the frequency and nature of CVAD-associated complications that
occur during the front-line treatment of patients with mCRC. Our
analysis shows that regimens based on an oral fluoropyrimidine
(e.g., XELOX) are preferable to infusional 5-FU (e.g., FOLFOX-4)
for the treatment of mCRC in the front-line setting with regard to
CVAD-associated complications, the need for CVAD replacement,
pump malfunctions and CVAD-associated adverse events, all of
which adversely impact upon patient well being. These findings
also have potentially important implications with respect to
adjuvant chemotherapy. The majority (80%) of CVAD-associated
adverse events occurred within 120 days of treatment initiation,
which is well within the usual 6-month duration of adjuvant
chemotherapy. Adjuvant therapy is given with curative intent, but
in reality, many patients are already cured by surgery and others
relapse despite adjuvant therapy. Only a relatively small proportion
of patients, therefore, directly benefit from adjuvant treatment.
For this reason, any risk of potentially serious complications
should be minimised. Thus, in this setting, oral fluoropyrimidine-
based chemotherapy with either the XELOX regimen or capeci-
tabine monotherapy may be a preferred treatment option when
compared with FOLFOX-4 or other infusional 5-FU regimens.
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